close

EQRx to Participate in the Jefferies 2022 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST.

A live and archived webcast of the fireside chat will be available by visiting the News & Events section of EQRx’s website, and selecting Events & Presentations, at investors.eqrx.com.

About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and health systems. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US LinkedIn, Instagram: @eqrxinc.

EQRx™ and Remaking Medicine™ are trademarks of EQRx.

EQRx Contacts:

Media:
Dan Budwick
1AB
dan@1abmedia.com

Investors:
investors@eqrx.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.06
+3.78 (1.84%)
AAPL  272.35
+6.17 (2.32%)
AMD  213.93
+17.33 (8.81%)
BAC  50.51
-0.56 (-1.11%)
GOOG  310.96
-0.73 (-0.23%)
META  639.01
+1.76 (0.28%)
MSFT  387.75
+3.28 (0.85%)
NVDA  192.57
+1.02 (0.54%)
ORCL  145.91
+4.60 (3.26%)
TSLA  408.81
+8.98 (2.25%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today